Genio

Mr. Green is a Co-Founder & CEO of Genio Technologies Inc. An experienced and successful executive and entrepreneur, Mr. Green is a dynamic leader with an unrelenting passion for advancing abstract concepts into flourishing and successful enterprises.  Mr. Green has a unique ability to interpret industry trends and business demands, which has contributed to him achieving multiple successful exits.  

Mr. Green is recognized as an expert in the development and implementation of growth strategies and performance improvement initiatives that generate and accelerate value creation for stakeholders and investors.  Mr. Green is deeply passionate about building first-in-class teams that foster innovation where experimentation is encouraged, and collaboration is an organizational cornerstone.  

B.S., The University of Oklahoma

Dr. Eberlin is a Co-Founder and Chief Scientific Officer of Genio Technologies, Inc. and an Assistant Professor in the Departments of Chemistry, Oncology, and Diagnostic Medicine at the University of Texas at Austin, and an adjunct Assistant Professor in the Department of Surgery at Baylor College of Medicine.  Dr. Eberlin is passionate about research at the intersection of chemistry and medicine. She has focused her career on developing innovative mass spectrometry technologies to address critical problems in healthcare. 

Dr. Eberlin received her B.S. in Chemistry from the State University of Campinas, her Ph.D. in Analytical Chemistry from Purdue University, and pursued her postdoctoral research in the Department of Chemistry at Stanford University. In 2016, Dr. Eberlin started her independent career as an assistant professor at The University of Texas at Austin. Eberlin is the recipient of many honors and awards for her scientific research, including an NIH Pathway to Independence Award, Forbes 30 under 30 listing in the Healthcare category, a Moore Inventor Fellowship, and most notably a MacArthur “Genius” Fellowship in 2018. Her research program centers around the development and application of novel mass spectrometry technologies in health-related research, with a particular focus on disease detection and diagnosis to improve patient care and clinical outcomes. Dr. Eberlin has published more than 65 research articles in top-rated journals such as PNAS, Science Translational Medicine, Nature Communications, Cancer Research, and Clinical Chemistry.

She is passionate about the representation of women and diversity in science and is an outspoken advocate for promoting women in higher levels of academia as well as leadership.

Ph.D., Purdue University

B.S., Universidade Estadual de Campinas

Dr. Suliburk is a Co-Founder and Chief Medical Officer of Genio Technologies, Inc.  He is a board-certified surgeon specializing in the treatment of tumors of the thyroid, parathyroid, and adrenal gland. As a fellowship-trained endocrine surgeon, he specializes in the care of patients with thyroid nodules, goiter, Graves’ disease, thyroid cancer, hyperparathyroidism, adrenal masses, pheochromocytoma, Cushing’s, and Conn’s diseases. His advanced surgical expertise includes minimally invasive parathyroidectomy and thyroidectomy, traditional open thyroidectomy, central, selective, and modified radical neck dissection, single incision laparoscopic adrenalectomy, and traditional laparoscopic adrenalectomy.
 Dr. Suliburk researches clinical outcomes in endocrine surgery in underserved and minority populations, outcomes in acute care and trauma surgery, the application of mobile technology to improve perioperative surgical care, and communication with patients to detect impending complications. His research program at Ben Taub Hospital and Baylor St. Luke’s CHI Medical Center offers opportunities in translational science, clinical outcomes, and mobile technology development/innovation.  

MD, University of Oklahoma College of Medicine

B.S., University of Oklahoma 

Dr. Zahedivash is responsible for identifying and developing strategies for clinical applications of the precìso MasSpec Pen System. He was involved in the early development of the MasSpec Pen as a biomedical engineer undergraduate student. He has years of experience in the development of other medical systems and diagnostic techniques. Dr. Zahedivash, who is a passionate longhorn, received engineering, medical, and business degrees all from the University of Texas at Austin. He is currently a resident physician at Stanford University.   

MD, The University of Texas at Austin

MBA, The University of Texas at Austin – McCombs School of Business

B.S., The University of Texas at Austin 

Dr. Feider is a Medical and Regulatory Affairs Specialist with Genio Technologies, 

Inc. She obtained her Ph.D. in chemistry in 2020 from the University of Texas at 

Austin, where she developed a passion for transitioning complex analytical tools 

from the laboratory to the clinic. Dr. Feider began working with the precìso MasSpec Pen

technology shortly after its invention in 2015 and has since been deeply involved in the research and development of the system as well as leading early clinical testing of the device.

Ph.D., The University of Texas at Austin

B.S., University of San Francisco 

Dr. Milner is a Co-Founder and Technology Advisor for Genio Technologies, Inc.  Dr. Milner is a prolific innovator who has secured 55 U.S. patents and five international patents, licensed to six companies. Dr. Milner has pioneered multiple technologies for surgical and diagnostic purposes, contributing greatly to many medical disciplines.  Dr. Milner is also co-founder of CardioSpectra and Dermalucent.  His patent royalties to university IP Owners/Licensees have returned over $100 million in revenue, and he has authored 190 peer-reviewed articles and eight book chapters. 

Ph.D., University of Arizona

M.S., Colorado School of Mines

B.S., Colorado School of Mines